Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients

por Lasnon, Charline, Desmonts, Cédric, Quak, Elske, Gervais, Radj, Do, Pascal, Dubos-Arvis, Catherine, Aide, Nicolas
Publicado 2013

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer

por Dumont, Delphine, Dô, Pascal, Lerouge, Delphine, Planchard, Gaëtane, Riffet, Marc, Dubos-Arvis, Catherine, Danhier, Serge, Gervais, Radj
Publicado 2017

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

por Auliac, Jean-Bernard, Dô, Pascal, Bayle, Sophie, Doubre, Hélène, Vinas, Florent, Letreut, Jacques, Falchero, Lionel, Hauss, Pierre Alexandre, Thomas, Pascal, Chouaid, Christos
Publicado 2019

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

por Lesueur, Paul, Escande, Alexandre, Thariat, Juliette, Vauléon, Enora, Monnet, Isabelle, Cortot, Alexis, Lerouge, Delphine, Danhier, Serge, Dô, Pascal, Dubos‐Arvis, Catherine, Chouaïd, Christos, Gervais, Radj
Publicado 2018

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL stud...

por Bennouna, Jaafar, Barlesi, Fabrice, Do, Pascal, Dumont, Patrick, Cadranel, Jacques, Debieuvre, Didier, Hilgers, Werner, Molinier, Olivier, Quoix, Elisabeth, Raimbourg, Judith, Langlais, Alexandra, Morin, Franck, Souquet, Pierre-Jean
Publicado 2018

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

por Vergnenegre, Alain, Geier, Margaux, Guisier, Florian, Lamy, Regine, Comet, Bénédicte, Le Garff, Gwenaelle, Do, Pascal, Janicot, Henri, Morel, Hugues, Decroisette, Chantal, Andre, Michel, Falchero, Lionel, Paleiron, Nicolas, Monnet, Isabelle
Publicado 2019

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

por Auliac, Jean-Bernard, Bayle, Sophie, Do, Pascal, Le Garff, Gwenaëlle, Roa, Magali, Falchero, Lionel, Huchot, Eric, Quéré, Gilles, Jeannin, Gaëlle, Métivier, Anne-Cécile, Hobeika, Joëlle, Guisier, Florian, Chouaid, Christos
Publicado 2020

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World B...

por Descourt, Renaud, Pérol, Maurice, Rousseau-Bussac, Gaëlle, Planchard, David, Mennecier, Bertrand, Wislez, Marie, Cadranel, Jacques, Cortot, Alexis Benjamin, Guisier, Florian, Galland, Loïck, Do, Pascal, Schott, Roland, Dansin, Éric, Arrondeau, Jennifer, Auliac, Jean-Bernard, Geier, Margaux, Chouaïd, Christos
Publicado 2022

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy f...

por Borget, Isabelle, Pérol, Maurice, Pérol, David, Lavolé, Armelle, Greillier, Laurent, Dô, Pascal, Westeel, Virginie, Crequit, Jacky, Léna, Hervé, Monnet, Isabelle, Le Caer, Hervé, Fournel, Pierre, Falchero, Lionel, Poudenx, Michel, Vaylet, Fabien, Chabaud, Sylvie, Vergnenegre, Alain, Zalcman, Gérard, Chouaïd, Christos
Publicado 2014

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

por Baldacci, Simon, Mazieres, Julien, Tomasini, Pascale, Girard, Nicolas, Guisier, Florian, Audigier-Valette, Clarisse, Monnet, Isabelle, Wislez, Marie, Pérol, Maurice, Dô, Pascal, Dansin, Eric, Leduc, Charlotte, Giroux Leprieur, Etienne, Moro-Sibilot, Denis, Tulasne, David, Kherrouche, Zoulika, Labreuche, Julien, Cortot, Alexis B.
Publicado 2017

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients

por Cadranel, Jacques, Cortot, Alexis B., Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin
Publicado 2018